No Muscle Depletion with High Visceral Fat as a Novel Beneficial Biomarker of Sorafenib for Hepatocellular Carcinoma | Zendy

Issei Saeki | Zendy; Takahiro Yamasaki | Zendy; Masaki Maeda | Zendy; Reo Kawano | Zendy; Takuro Hisanaga | Zendy; Takuya Iwamoto | Zendy; Toshihiko Matsumoto | Zendy; Isao Hidaka | Zendy; Tsuyoshi Ishikawa | Zendy; Taro Takami | Zendy; Isao Sakaida | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

No Muscle Depletion with High Visceral Fat as a Novel Beneficial Biomarker of Sorafenib for Hepatocellular Carcinoma

Author(s) -

Issei Saeki,

Takahiro Yamasaki,

Masaki Maeda,

Reo Kawano,

Takuro Hisanaga,

Takuya Iwamoto,

Toshihiko Matsumoto,

Isao Hidaka,

Tsuyoshi Ishikawa,

Taro Takami,

Isao Sakaida

Publication year - 2018

Publication title -

liver cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.916

H-Index - 34

eISSN - 2235-1795

pISSN - 1664-5553

DOI - 10.1159/000487858

Subject(s) - sorafenib , hepatocellular carcinoma , biomarker , medicine , visceral fat , cancer research , oncology , gastroenterology , chemistry , obesity , biochemistry , insulin resistance

Sorafenib is a standard therapy for patients with advanced hepatocellular carcinoma (HCC). However, no predictive biomarkers of sorafenib efficacy have been discovered. Herein, we investigated the impact of body composition, such as skeletal muscle and visceral fat, on the prognosis of advanced HCC patients treated with sorafenib.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research